Last reviewed · How we verify
Lenali
At a glance
| Generic name | Lenali |
|---|---|
| Sponsor | Singapore General Hospital |
| Target | Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Follicular lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Multiple myeloma
- Myelodysplastic syndrome
Common side effects
- Diarrhea
- Anemia
- Constipation
- Peripheral edema
- Neutropenia
- Fatigue
- Back pain
- Nausea
- Asthenia
- Insomnia
- Infection
- Thrombocytopenia
Serious adverse events
- Infection
- DVT
- Pneumonia
- Asthenia
- Fatigue
- Neutropenia
- Thrombocytopenia
- Anemia
- Dyspnea
- Hyperglycemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |